Patient Preference and Sensory Perception of Three Intranasal Corticosteroids for Allergic Rhinitis

Bunnag, Chaweewan; Suprihati,; Wang, Deyun

doi:10.2165/00044011-200323010-00005

Cited by 4 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…17 Clinical studies in subjects with AR suggest that certain sensory attributes of INCSs, including nasal irritation, nasal run-out, and rundown to the back of the throat, can influence patient preference for a particular product. 13,14 This study was conducted in subjects with AR, unlike most deposition studies, which have been conducted in healthy volunteers. The CIC-HFA nasal aerosol formulation administers a lower spray volume in clinical use relative to most aqueous sprays.…”

Section: Discussionmentioning

confidence: 99%

“…12 Certain sensory attributes of INCSs, such as rundown to the back of the throat, run-out from the nose, and nasal irritation, can influence patient treatment preferences and, perhaps, patient adherence to therapy. [13][14][15][16] Findings from the Allergies in America adult survey and The Nasal Allergy Survey Assessing Limitations reveal that ϳ40% of patients with AR report rundown to the back of the throat as a bothersome side effect of their intranasal aqueous medications and as a common reason for patients requesting a change in their AR medication. 1,17 This study, for the first time, compared the nasal deposition and retention of CIC-HFA aerosol with mometasone furoate monohydrate aqueous nasal spray (MFNS) in subjects with AR, using a radioactive tracer as a surrogate for deposition and retention of the vehicle for each of these nasal formulations.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Nasal Deposition of Ciclesonide Nasal Aerosol and Mometasone Aqueous Nasal Spray in Allergic Rhinitis Patients

Emanuel¹,

Blaiss²,

Meltzer

et al. 2014

Am J Rhinol�Allergy

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Nasal Deposition of Ciclesonide Nasal Aerosol and Mometasone Aqueous Nasal Spray in Allergic Rhinitis Patients

Emanuel¹,

Blaiss²,

Meltzer

et al. 2014

Am J Rhinol�Allergy

View full text Add to dashboard Cite

show abstract

“…Fluticasone furoate was preferred over mometasone furoate after treatment for 2 weeks, 38 and triamcinolone acetonide was preferred over mometasone furoate in several single-dose studies. 42 , 45 , 46 Notably, fluticasone furoate was preferred over fluticasone propionate in terms of having less odor/scent, causing less nose runout/throat rundown, and having less aftertaste. 39 Thus, even though a pat ent may not have liked the sensory attributes of fluticasone propionate in the past, this should not preclude the use of fluticasone furoate given the differences in sensory perception.…”

Section: Barriers To the Use Of Incsmentioning

confidence: 99%

Overcoming barriers to intranasal corticosteroid use in patients with uncontrolled allergic rhinitis

Bridgeman¹

2017

IPRP

View full text Add to dashboard Cite

Patients suffering from allergic rhinitis often attempt to self-manage their symptoms and may seek advice from pharmacists about nonprescription product choices. Several drug classes, both prescription and over-the-counter (OTC), are available, including intranasal corticosteroids (INCSs); oral, intranasal, and ocular antihistamines; leukotriene antagonists; and topical and systemic decongestants, as well as immunotherapies. Selection of the optimal treatment approach depends on the temporal pattern, frequency, and severity of symptoms as well as the patient’s age. Nasal congestion is typically the most bothersome symptom, although rhinorrhea, postnasal drip, and ocular symptoms are also problematic. Together, these symptoms may adversely impact the quality of life, work productivity, sleep quality, and the ability to perform daily activities, particularly when uncontrolled. Practice guidelines recognize that INCSs are the most effective medications for controlling allergic rhinitis symptoms, including nasal congestion. Available INCS products have comparable safety and efficacy profiles, but they differ in formulation characteristics and sensory attributes. Several barriers can impede the use of INCSs, including concerns about safety, misperceptions regarding the loss of response from frequent use, and undesirable sensations associated with intranasal administration. Given the increasing number of INCSs available OTC, pharmacists can help allay these concerns by discussing treatment expectations, recommending INCS products with favorable formulation characteristics, and reviewing proper use and technique for the administration of the selected product. These steps can help to foster a collaborative relationship between the patient and the pharmacist in the treatment of allergic rhinitis.

show abstract

“…Because of this slow onset and the need for regular treatment to maintain efficacy, it is important when using INSs to provide comprehensive explanations to patients so as to improve compliance. Many factors affect compliance, including sensory attributes of the sprays [56, 57], local side‐effects (bleeding, yeast infections), and patient education. Even with thorough patient education, a substantial number (11%) of INS patients still fail to take 50% of treatment doses, resulting in poor outcomes [58].…”

Section: Pharmacotherapiesmentioning

confidence: 99%

Management of persistent allergic rhinitis in the tropics: Singapore experiences

Gordon

2008

Clin Exp All Rev

View full text Add to dashboard Cite

Allergic rhinitis (AR) is a common manifestation of allergic diseases, affecting X10-25% of the world's population. In the tropics, the majority of AR is persistent. The year-round warm, humid climate is conducive for the proliferation of dust mites and moulds, two of the most common aeroallergens implicated in persistent allergic rhinitis (PAR). The management of AR includes patient education, allergen avoidance, pharmacological treatment, and specific immunotherapy. Patient education, especially regarding dust and mould exposure reduction, can be effective but is often under-utilized. Second generation, non-sedating H 1antihistamines rapidly relieve most nasal symptoms because they effectively block the histamine H 1 -receptors that trigger plasma exudation and oedema. Congestion is most effectively controlled by intranasal glucocorticosteroids (INSs), which are currently the most potent AR drug treatment. The beneficial effects of steroids depend on their long-term, multipathway anti-inflammatory effects, unlike H 1 -antihistamines, which directly block neural and vascular H 1 receptors. However, especially in PAR, patients' compliance with INS therapy has a significant impact on treatment efficacy, because year-round treatment is required. Subcutaneous inhalant allergen immunotherapy (SCIT) is effective against a broad range of AR symptoms, and may be able to alter the natural course of allergy and prevent asthma onset. SCIT can significantly reduce the severity of allergic disease, including nasal obstruction, and decrease the need for anti-allergic drugs. Immunotherapy (IT) can also be given as sublingual drops (SLIT). Recent studies have shown the SLIT to be effective in reducing AR symptoms and medication use. Both types of IT require long-term patient compliance for successful treatment. Drug and IT interventions may not be economically feasible in certain patients. In conclusion, the type of AR most prevalent in the tropics is PAR, which must be treated year round. Improvement of educational programmes for the public and physicians alike seems to be the most effective treatment strategy.

show abstract

Patient Preference and Sensory Perception of Three Intranasal Corticosteroids for Allergic Rhinitis

Abstract: The results of this study indicate that TAA is the most favourable nasal spray in terms of preference and sensory perceptions for patients with perennial or seasonal allergic rhinitis.

Cited by 4 publications

References 10 publications

Nasal Deposition of Ciclesonide Nasal Aerosol and Mometasone Aqueous Nasal Spray in Allergic Rhinitis Patients

Nasal Deposition of Ciclesonide Nasal Aerosol and Mometasone Aqueous Nasal Spray in Allergic Rhinitis Patients

Overcoming barriers to intranasal corticosteroid use in patients with uncontrolled allergic rhinitis

Management of persistent allergic rhinitis in the tropics: Singapore experiences

Contact Info

Product

Resources

About